Alteration and significance of serum lipid levels and nutritional status during BCMA-CAR-T-cell therapy in patients with refractory or relapsed multiple myeloma: a retrospective study based on LEGEND-2
To explore the dynamic changes in serum lipid levels and nutritional status during BCMA-CAR-T-cell therapy in patients with refractory or relapsed multiple myeloma (R/R MM) based on LEGEND-2. The data of patients with R/R MM who underwent BCMA-CAR-T therapy at our hospital between March 30, 2016, an...
Gespeichert in:
| Veröffentlicht in: | Zhōnghuá xuèyèxué zázhì 2023-10, Vol.44 (10), p.838-844 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | chi |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 844 |
|---|---|
| container_issue | 10 |
| container_start_page | 838 |
| container_title | Zhōnghuá xuèyèxué zázhì |
| container_volume | 44 |
| creator | Xu, X Z Liu, R Zhao, W H Yang, Y Liu, J Zhang, W G Bai, J He, A L |
| description | To explore the dynamic changes in serum lipid levels and nutritional status during BCMA-CAR-T-cell therapy in patients with refractory or relapsed multiple myeloma (R/R MM) based on LEGEND-2.
The data of patients with R/R MM who underwent BCMA-CAR-T therapy at our hospital between March 30, 2016, and February 6, 2018, were retrospectively collected. Serum lipid levels, controlled nutritional status (CONUT) score, and other clinical indicators at different time points before and after CAR-T-cell infusion were compared and analyzed. The best cut-off value was determined by using the receiver operator characteristic (ROC) curve. The patients were divided into high-CONUT score (>6.5 points, malnutrition group) and low-CONUT score groups (≤6.5 points, good nutrition group), comparing the progression-free survival (PFS) and total survival (OS) of the two groups using Kaplan-Meier survival analysis.
Before the infusion of CAR-T-cells, excluding triglycerides (TG), patients' serum lipid levels were lower than normal |
| doi_str_mv | 10.3760/cma.j.issn.0253-2727.2023.10.008 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_2898314173</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2898314173</sourcerecordid><originalsourceid>FETCH-LOGICAL-p126t-4dc78c0e0798ac34f9fb17d108153f3efbcc6e16bd0a5b6fda6d4c3127c046043</originalsourceid><addsrcrecordid>eNo9kE1vFDEMhnMA0ar0LyAfe5khH7OZWW7LshSkBSRUzqtM4rRBmUzIR9H8RP4Vs1A4WbYfv69tQm4YbUUv6Ws9qfZ763IOLeUb0fCe9y2nXLQrQenwjFz-r1-Q65zdSDdMyEEI-oJciIF2WyHkJfm18wWTKm4OoIKB7O6Ds06roBFmCxlTncC76Ax4fESf_2ChluTOQ8pDLqrUDKYmF-7h7f7TrtnvvjZ3jUbvoTys8nEBFyCuNhhKhp-uPEBCm5Quc1pgTmvmVcxoYKq-uOgRpgX9PKk3oNZmSXOOqIt7xNWvmgVGdabXrY-H28Pndw1_SZ5b5TNeP8Ur8u394W7_oTl-uf243x2byLgsTWd0P2iKtN8OSovObu3IesPowDbCCrSj1hKZHA1Vm1Fao6TptGC817STtBNX5Oavbkzzj4q5nCaXz6eqgHPNJz5sB8E61osVffWE1nFCc4rJTSotp3_vF78BE-aPBg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2898314173</pqid></control><display><type>article</type><title>Alteration and significance of serum lipid levels and nutritional status during BCMA-CAR-T-cell therapy in patients with refractory or relapsed multiple myeloma: a retrospective study based on LEGEND-2</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Xu, X Z ; Liu, R ; Zhao, W H ; Yang, Y ; Liu, J ; Zhang, W G ; Bai, J ; He, A L</creator><creatorcontrib>Xu, X Z ; Liu, R ; Zhao, W H ; Yang, Y ; Liu, J ; Zhang, W G ; Bai, J ; He, A L</creatorcontrib><description>To explore the dynamic changes in serum lipid levels and nutritional status during BCMA-CAR-T-cell therapy in patients with refractory or relapsed multiple myeloma (R/R MM) based on LEGEND-2.
The data of patients with R/R MM who underwent BCMA-CAR-T therapy at our hospital between March 30, 2016, and February 6, 2018, were retrospectively collected. Serum lipid levels, controlled nutritional status (CONUT) score, and other clinical indicators at different time points before and after CAR-T-cell infusion were compared and analyzed. The best cut-off value was determined by using the receiver operator characteristic (ROC) curve. The patients were divided into high-CONUT score (>6.5 points, malnutrition group) and low-CONUT score groups (≤6.5 points, good nutrition group), comparing the progression-free survival (PFS) and total survival (OS) of the two groups using Kaplan-Meier survival analysis.
Before the infusion of CAR-T-cells, excluding triglycerides (TG), patients' serum lipid levels were lower than normal</description><identifier>ISSN: 0253-2727</identifier><identifier>DOI: 10.3760/cma.j.issn.0253-2727.2023.10.008</identifier><identifier>PMID: 38049336</identifier><language>chi</language><publisher>China</publisher><subject>B-Cell Maturation Antigen - therapeutic use ; Cell- and Tissue-Based Therapy ; Humans ; Lipids - therapeutic use ; Multiple Myeloma - drug therapy ; Nutritional Status ; Receptors, Chimeric Antigen - therapeutic use ; Retrospective Studies</subject><ispartof>Zhōnghuá xuèyèxué zázhì, 2023-10, Vol.44 (10), p.838-844</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38049336$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Xu, X Z</creatorcontrib><creatorcontrib>Liu, R</creatorcontrib><creatorcontrib>Zhao, W H</creatorcontrib><creatorcontrib>Yang, Y</creatorcontrib><creatorcontrib>Liu, J</creatorcontrib><creatorcontrib>Zhang, W G</creatorcontrib><creatorcontrib>Bai, J</creatorcontrib><creatorcontrib>He, A L</creatorcontrib><title>Alteration and significance of serum lipid levels and nutritional status during BCMA-CAR-T-cell therapy in patients with refractory or relapsed multiple myeloma: a retrospective study based on LEGEND-2</title><title>Zhōnghuá xuèyèxué zázhì</title><addtitle>Zhonghua Xue Ye Xue Za Zhi</addtitle><description>To explore the dynamic changes in serum lipid levels and nutritional status during BCMA-CAR-T-cell therapy in patients with refractory or relapsed multiple myeloma (R/R MM) based on LEGEND-2.
The data of patients with R/R MM who underwent BCMA-CAR-T therapy at our hospital between March 30, 2016, and February 6, 2018, were retrospectively collected. Serum lipid levels, controlled nutritional status (CONUT) score, and other clinical indicators at different time points before and after CAR-T-cell infusion were compared and analyzed. The best cut-off value was determined by using the receiver operator characteristic (ROC) curve. The patients were divided into high-CONUT score (>6.5 points, malnutrition group) and low-CONUT score groups (≤6.5 points, good nutrition group), comparing the progression-free survival (PFS) and total survival (OS) of the two groups using Kaplan-Meier survival analysis.
Before the infusion of CAR-T-cells, excluding triglycerides (TG), patients' serum lipid levels were lower than normal</description><subject>B-Cell Maturation Antigen - therapeutic use</subject><subject>Cell- and Tissue-Based Therapy</subject><subject>Humans</subject><subject>Lipids - therapeutic use</subject><subject>Multiple Myeloma - drug therapy</subject><subject>Nutritional Status</subject><subject>Receptors, Chimeric Antigen - therapeutic use</subject><subject>Retrospective Studies</subject><issn>0253-2727</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kE1vFDEMhnMA0ar0LyAfe5khH7OZWW7LshSkBSRUzqtM4rRBmUzIR9H8RP4Vs1A4WbYfv69tQm4YbUUv6Ws9qfZ763IOLeUb0fCe9y2nXLQrQenwjFz-r1-Q65zdSDdMyEEI-oJciIF2WyHkJfm18wWTKm4OoIKB7O6Ds06roBFmCxlTncC76Ax4fESf_2ChluTOQ8pDLqrUDKYmF-7h7f7TrtnvvjZ3jUbvoTys8nEBFyCuNhhKhp-uPEBCm5Quc1pgTmvmVcxoYKq-uOgRpgX9PKk3oNZmSXOOqIt7xNWvmgVGdabXrY-H28Pndw1_SZ5b5TNeP8Ur8u394W7_oTl-uf243x2byLgsTWd0P2iKtN8OSovObu3IesPowDbCCrSj1hKZHA1Vm1Fao6TptGC817STtBNX5Oavbkzzj4q5nCaXz6eqgHPNJz5sB8E61osVffWE1nFCc4rJTSotp3_vF78BE-aPBg</recordid><startdate>20231014</startdate><enddate>20231014</enddate><creator>Xu, X Z</creator><creator>Liu, R</creator><creator>Zhao, W H</creator><creator>Yang, Y</creator><creator>Liu, J</creator><creator>Zhang, W G</creator><creator>Bai, J</creator><creator>He, A L</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20231014</creationdate><title>Alteration and significance of serum lipid levels and nutritional status during BCMA-CAR-T-cell therapy in patients with refractory or relapsed multiple myeloma: a retrospective study based on LEGEND-2</title><author>Xu, X Z ; Liu, R ; Zhao, W H ; Yang, Y ; Liu, J ; Zhang, W G ; Bai, J ; He, A L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p126t-4dc78c0e0798ac34f9fb17d108153f3efbcc6e16bd0a5b6fda6d4c3127c046043</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>chi</language><creationdate>2023</creationdate><topic>B-Cell Maturation Antigen - therapeutic use</topic><topic>Cell- and Tissue-Based Therapy</topic><topic>Humans</topic><topic>Lipids - therapeutic use</topic><topic>Multiple Myeloma - drug therapy</topic><topic>Nutritional Status</topic><topic>Receptors, Chimeric Antigen - therapeutic use</topic><topic>Retrospective Studies</topic><toplevel>online_resources</toplevel><creatorcontrib>Xu, X Z</creatorcontrib><creatorcontrib>Liu, R</creatorcontrib><creatorcontrib>Zhao, W H</creatorcontrib><creatorcontrib>Yang, Y</creatorcontrib><creatorcontrib>Liu, J</creatorcontrib><creatorcontrib>Zhang, W G</creatorcontrib><creatorcontrib>Bai, J</creatorcontrib><creatorcontrib>He, A L</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Zhōnghuá xuèyèxué zázhì</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Xu, X Z</au><au>Liu, R</au><au>Zhao, W H</au><au>Yang, Y</au><au>Liu, J</au><au>Zhang, W G</au><au>Bai, J</au><au>He, A L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Alteration and significance of serum lipid levels and nutritional status during BCMA-CAR-T-cell therapy in patients with refractory or relapsed multiple myeloma: a retrospective study based on LEGEND-2</atitle><jtitle>Zhōnghuá xuèyèxué zázhì</jtitle><addtitle>Zhonghua Xue Ye Xue Za Zhi</addtitle><date>2023-10-14</date><risdate>2023</risdate><volume>44</volume><issue>10</issue><spage>838</spage><epage>844</epage><pages>838-844</pages><issn>0253-2727</issn><abstract>To explore the dynamic changes in serum lipid levels and nutritional status during BCMA-CAR-T-cell therapy in patients with refractory or relapsed multiple myeloma (R/R MM) based on LEGEND-2.
The data of patients with R/R MM who underwent BCMA-CAR-T therapy at our hospital between March 30, 2016, and February 6, 2018, were retrospectively collected. Serum lipid levels, controlled nutritional status (CONUT) score, and other clinical indicators at different time points before and after CAR-T-cell infusion were compared and analyzed. The best cut-off value was determined by using the receiver operator characteristic (ROC) curve. The patients were divided into high-CONUT score (>6.5 points, malnutrition group) and low-CONUT score groups (≤6.5 points, good nutrition group), comparing the progression-free survival (PFS) and total survival (OS) of the two groups using Kaplan-Meier survival analysis.
Before the infusion of CAR-T-cells, excluding triglycerides (TG), patients' serum lipid levels were lower than normal</abstract><cop>China</cop><pmid>38049336</pmid><doi>10.3760/cma.j.issn.0253-2727.2023.10.008</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0253-2727 |
| ispartof | Zhōnghuá xuèyèxué zázhì, 2023-10, Vol.44 (10), p.838-844 |
| issn | 0253-2727 |
| language | chi |
| recordid | cdi_proquest_miscellaneous_2898314173 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | B-Cell Maturation Antigen - therapeutic use Cell- and Tissue-Based Therapy Humans Lipids - therapeutic use Multiple Myeloma - drug therapy Nutritional Status Receptors, Chimeric Antigen - therapeutic use Retrospective Studies |
| title | Alteration and significance of serum lipid levels and nutritional status during BCMA-CAR-T-cell therapy in patients with refractory or relapsed multiple myeloma: a retrospective study based on LEGEND-2 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T01%3A11%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Alteration%20and%20significance%20of%20serum%20lipid%20levels%20and%20nutritional%20status%20during%20BCMA-CAR-T-cell%20therapy%20in%20patients%20with%20refractory%20or%20relapsed%20multiple%20myeloma:%20a%20retrospective%20study%20based%20on%20LEGEND-2&rft.jtitle=Zh%C5%8Dnghu%C3%A1%20xu%C3%A8y%C3%A8xu%C3%A9%20z%C3%A1zh%C3%AC&rft.au=Xu,%20X%20Z&rft.date=2023-10-14&rft.volume=44&rft.issue=10&rft.spage=838&rft.epage=844&rft.pages=838-844&rft.issn=0253-2727&rft_id=info:doi/10.3760/cma.j.issn.0253-2727.2023.10.008&rft_dat=%3Cproquest_pubme%3E2898314173%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2898314173&rft_id=info:pmid/38049336&rfr_iscdi=true |